Visara, Inc. confronts a medium-likelihood risk of depleting capital before its lead candidate VIS-101 reaches market, according to a February 2026 risk assessment. The NovaBridge subsidiary co-founded by Dr. Cunningham is developing the biologic therapeutic for wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
Ophthalmology drug development carries exceptional costs. Phase III trials for retinal disease treatments typically require $100-300 million, with timelines stretching 3-5 years before potential FDA approval. Visara must fund these expenses before generating any revenue.
The capital crunch hits biotech broadly. Q4 2025 saw biotech venture funding drop 23% year-over-year to $8.2 billion, per PitchBook data. Early-stage ophthalmology companies face particular pressure: investors demand proof-of-concept data requiring $50-80 million in Series B funding, yet 67% of ophthalmology biotechs fail to secure follow-on financing after Series A.
VIS-101 targets a substantial market. Wet AMD affects 1.5 million Americans, while DME impacts 750,000 diabetic patients. Current anti-VEGF treatments generate $7 billion annually, led by Regeneron's Eylea and Roche's Lucentis. Novel biologics capturing even 10% market share could produce $700 million in peak sales.
The funding gap creates stark outcomes. Companies exhausting runway before commercialization face asset fire-sales at 30-50% discounts, wiping out investor returns. Alternative paths include dilutive down-rounds, licensing deals surrendering 60-80% of economics, or outright shutdowns.
Parent company NovaBridge's support remains unclear. Corporate parents typically limit subsidiary cash injections to $20-40 million absent exceptional circumstances, insufficient to bridge VIS-101 to market.
Strategic options exist. Partnerships with Big Pharma could provide $150-250 million upfront plus milestones, though requiring equity stakes of 40-60%. SPAC mergers or IPOs remain possible if capital markets rebound, but 2025's biotech IPO drought—just 18 deals versus 93 in 2021—signals continued difficulty.
The assessment assigns 70% confidence to this capital depletion risk, reflecting uncertainties in development timelines, regulatory requirements, and financing availability. For investors, the scenario underscores biotech's binary outcomes: breakthrough returns or total loss.